Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
| Autor: | Christopher Gallagher, Elizabeth Butts, Marjolaine Gauthier-Loiselle, Eric Q. Wu, Raluca Ionescu-Ittu, Tripthi Kamath, Anthony Masaquel, Nicholas Sicignano, Brian Barnett, Roy Nitulescu, Kenneth More, Annie Guerin |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment 03 medical and health sciences 0302 clinical medicine Breast cancer Trastuzumab Internal medicine medicine Overall survival In patient 030212 general & internal medicine Relapse Stage (cooking) HER2-positive breast cancer skin and connective tissue diseases Multidisciplinary business.industry Research medicine.disease Confidence interval Clinical Practice 030220 oncology & carcinogenesis business Adjuvant medicine.drug |
| Zdroj: | SpringerPlus |
| ISSN: | 2193-1801 |
| Popis: | Purpose The NSABP Trial B-31 and NCCTG Trial N9831 (B-31/N9831 trials, Romond et al. in N Engl J Med 353:1673–84, 2005. doi:10.1056/NEJMoa052122; Perez et al. in J Clin Oncol 32:3744–52, 2014. doi:10.1200/JCO.2014.55.5730) established the efficacy of adjuvant trastuzumab for patients with HER2-positive early stage breast cancer. We aimed to estimate the overall survival (OS) and relapse-free survival (RFS) of HER2-positive non-metastatic breast cancer patients treated with adjuvant trastuzumab in a clinical practice setting in the United States. Methods Adult women initiating adjuvant trastuzumab within 1 year of breast cancer surgery were identified in the health claims database of the US Department of Defense (01/2003–12/2012). OS and RFS unadjusted rates at 4 and 6 years after the first trastuzumab treatment following the breast cancer diagnosis were estimated from Kaplan–Meier analyses. Results The study sample included 3188 women followed for a median of 3.3 years after trastuzumab initiation and treated continuously with trastuzumab for a median of 12 months. The OS rates (95 % confidence intervals) at 4 and 6 years were 90.0 % (88.6–91.2) and 87.1 (85.3–88.6), respectively. The corresponding RFS rates were 75.8 % (74.0–77.5) and 72.7 (70.7–74.7), respectively. The OS and RFS rates at 6 years reported in the B-31/N9831 trials were 89.8 and 81.4 %, respectively. Conclusions OS rates estimated in this study were in range with those estimated in the B-31/N9831 trials, while RFS rates were lower. However, patients in the B-31/N9831 trials were younger and possibly had fewer comorbidities than patients in the current study; these differences were not adjusted for in the crude OS and RFS analyses. Electronic supplementary material The online version of this article (doi:10.1186/s40064-016-2008-9) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink